Recent studies have further implicatedPLK2 as a context-dependentoncogene in various solid tumors, including colorectal, pancreatic,and ovarian cancers., While initially considered a tumorsuppressor via its engagement in the p53-mediated DNA damage response,PLK2 has been shown to promote tumor progression in settings characterizedby oxidative stress or dysfunctional p53 signaling. In cancer cells, PLK2 supports survival by enhancing chemoresistanceand redox adaptation through phosphorylation of key downstream effectorssuch as GSK3β and NRF2. The gene discussed is TP53; the disease is ovarian carcinoma.